GSK to Buy Affinivax for Up to $3.3 Billion
31 May 2022 - 4:43PM
Dow Jones News
By Kyle Morris
GSK PLC said Tuesday that it has agreed to buy clinical-stage
biopharmaceutical company Affinivax, Inc. for up to $3.3
billion.
The healthcare company said that it will pay $2.1 billion
upfront and up to $1.2 billion in potential development milestones
and that the deal is expected to close in the third quarter.
The transaction will provide access to next-generation
pneumococcal vaccine candidates and support the development of its
vaccines and specialty medicines, GSK said.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
May 31, 2022 02:28 ET (06:28 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
